Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of a New Formulation of Tetravalent Dengue Vaccine (TDV) in Healthy Adults
NCT07047521Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
A Phase 3 trial of dengue tetravalent vaccine (live, attenuated) in dengue fever, sponsored by Takeda. Started Nov 2025; status: active, not recruiting.
02
Drugs
dengue tetravalent vaccine (live, attenuated)
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT07047521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047521.